Micrus Endovascular Corporation announced the initiation of its launch of Cerecyte® and stretch resistant versions of its DeltaPaq™ microcoil system for the treatment of cerebral aneurysms.
The novel DeltaPaq system is designed to achieve 10% to 20% greater intra-aneurysmal packing density than conventional microcoils. We are excited about the launch of the DeltaPaq microcoil, designed to enable physicians to achieve greater packing density, which we believe may result in improved outcomes,” commented John Kilcoyne, Chairman and CEO of Micrus Endovascular. “Greater packing density could reduce the rate of recanalization and, therefore, re-treatment. We believe the DeltaPaq microcoil system supplements our framing and finishing coils by materially improving our competitive position in the filling segment of the coil market.”
Micrus develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists, interventional neurologists and neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke.